Bioprocess Design and Optimization of Extracellular Vesicles Derived from Mesenchymal Stromal Cells
Dehghani M., Chai M., Talebloo N., Morrissey M., Larey A., Keselman P.
Laboratory Study, published in ACS Nano (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- ACS Nano (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42144976
- PMCID
- PMC13235650
- DOI
- 10.1021/acsnano.5c19046
Abstract (original English)
The development of extracellular-vesicle-based therapeutics requires robust analytical assays and scalable downstream processing strategies to ensure product quality and reproducibility. In this study, we established an analytical toolbox comprising scattering and fluorescence mode nanoparticle tracking analysis, fluorescence-based flow cytometry, and multidetector analytical size-exclusion chromatography. Liposomes, selected for their biophysical similarity to EVs, were used as reference materials to optimize assay parameters, fluorescence labeling conditions, and dynamic range, minimizing artifacts such as photobleaching and masking effects. Using these optimized analytical tools, we established a scalable downstream processing (DSP) workflow for human bone marrow mesenchymal stromal cell-derived EVs (MSC-EVs), incorporating clarification, tangential flow filtration, ion exchange chromatography, buffer exchange, and sterile filtration. We first designed and optimized the DSP process at small scale using ion exchange chromatography (IEX). We integrated controls such as medium-alone control to ensure the cell-secreted nature of the final preparation. Using a stepwise elution strategy, IEX chromatography resulted in the elution of two cell-secreted populations. We then investigated the identities of these two IEX eluates using orthogonal analytical techniques. Transmission elect
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.